6:38 PM
 | 
Oct 05, 2018
 |  BioCentury  |  Politics, Policy & Law

SUPPORTing FDA’s fight against opioids abuse

How the SUPPORT Act gives FDA new tools to combat the opioid abuse epidemic

Legislation President Donald Trump is expected to sign soon gives FDA powers that are intended to blunt the opioid abuse epidemic and incentivize development of non-addictive pain treatments.

The new authorities will give FDA tools it can use to slow the growth of opioid addiction stemming from careless prescribing, create scientific and medical opportunities for reducing patient exposure to opioids, and force drug manufacturers for the first time to develop data on the effects of long-term, chronic exposure to opioids. It may lead to restrictions on long-term use of certain opioids.

The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, which has passed both houses of Congress, also funds the creation and expansion of comprehensive opioid recovery centers that are designed to bring addiction and abuse treatment from poorly regulated operations run out of storefronts and strip malls into the medical mainstream (see “Sidebar: Getting Comprehensive”).


Sidebar: Getting comprehensive

Read the full 1974 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >